SRT-1720 HCl | CAS#1001645-58-4 | SIRT1 Activator

MedKoo Cat#: 407966 | Name: SRT-1720 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SRT-1720, also known as CAY10559 and is a drug developed by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. It has similar activity in the body to the known SIRT1 activator resveratrol, but is 1000x more potent. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function. A study of SRT1720 conducted by the National Institute on Aging found that the drug may extend the lifespan of obese mice by 44% .

Chemical Structure

SRT-1720 HCl

CAS#1001645-58-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 407966

Name: SRT-1720 HCl

CAS#: 1001645-58-4 (HCl)

Chemical Formula: C25H25Cl2N7OS

Exact Mass: 0.0000

Molecular Weight: 542.48

Elemental Analysis: C, 55.35; H, 4.65; Cl, 13.07; N, 18.07; O, 2.95; S, 5.91

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,850.00	2 Weeks
2g	USD 5,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

925434-55-5 (free base) 1001645-58-4 (HCl)

Synonym

SRT-1720 HCl, SRT-1720 hydrochloride; SRT1720; SRT-1720; SRT 1720; CAY10559; CAY-10559; CAY 10559; SIRT-1933; SIRT 1933; SIRT1933.

IUPAC/Chemical Name

N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide dihydrochloride

InChi Key

YBWQTKUVUFMWOX-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H23N7OS.2ClH/c33-24(22-13-27-20-7-3-4-8-21(20)28-22)29-19-6-2-1-5-18(19)23-15-32-17(16-34-25(32)30-23)14-31-11-9-26-10-12-31;;/h1-8,13,15-16,26H,9-12,14H2,(H,29,33);2*1H

SMILES Code

O=C(NC1=CC=CC=C1C2=CN3C(SC=C3CN4CCNCC4)=N2)C5=NC6=CC=CC=C6N=C5.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM and shows less potent activities agaiinst SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.

In vitro activity:

SRT1720 alters the brain's energy usage patterns. When SRT1720 was added to guinea pig brain cortical tissue slices, SRT1720 significantly increased 13C incorporation into Krebs cycle metabolites, as well as GABA and glutamine, while decreasing glycolysis-associated metabolites. SRT1720 increased label incorporation from [1,2-13C]acetate, indicating enhanced acetate metabolism with active SIRT1. SRT1720 increased glutamine levels and decreased lactate levels without affecting other measured metabolite pools. J Neurochem. 2017 Mar;140(6):903-918. https://pubmed.ncbi.nlm.nih.gov/27925207/

In vivo activity:

This study highlights SIRT1 as a potential target for treating kidney injuries caused by ischemia-reperfusion. Treating mice SRT1720 reduced kidney damage and improved kidney health. SRT1720 increased cell growth in adult mice after injury. SRT1720 also decreased the expression of p53 in the kidneys. These findings suggest SIRT1 with SRT-1720 can help reduce damage and promote kidney regeneration. Kidney Int. 2013 Mar;83(3):404-13. https://pubmed.ncbi.nlm.nih.gov/23302720/

	Solvent	mg/mL	mM
Solubility
	DMSO	38.0	75.09

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 542.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Rowlands BD, Klugmann M, Rae CD. Acetate metabolism does not reflect astrocytic activity, contributes directly to GABA synthesis, and is increased by silent information regulator 1 activation. J Neurochem. 2017 Mar;140(6):903-918. doi: 10.1111/jnc.13916. Epub 2017 Jan 23. PMID: 27925207. 2. Liang D, Zhuo Y, Guo Z, He L, Wang X, He Y, Li L, Dai H. SIRT1/PGC-1 pathway activation triggers autophagy/mitophagy and attenuates oxidative damage in intestinal epithelial cells. Biochimie. 2020 Mar;170:10-20. doi: 10.1016/j.biochi.2019.12.001. Epub 2019 Dec 9. PMID: 31830513. In vivo study 1. Jiang T, Liu E, Li Z, Yan C, Zhang X, Guan J, Zhan Y, Zhao B, Ding W. SIRT1-Rab7 axis attenuates NLRP3 and STING activation through late endosomal-dependent mitophagy during sepsis-induced acute lung injury. Int J Surg. 2024 Mar 4. doi: 10.1097/JS9.0000000000001215. Epub ahead of print. PMID: 38445453. 2. Fan H, Yang HC, You L, Wang YY, He WJ, Hao CM. The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int. 2013 Mar;83(3):404-13. doi: 10.1038/ki.2012.394. Epub 2013 Jan 9. PMID: 23302720.

In vitro protocol:

In vivo protocol:

1. Jiang T, Liu E, Li Z, Yan C, Zhang X, Guan J, Zhan Y, Zhao B, Ding W. SIRT1-Rab7 axis attenuates NLRP3 and STING activation through late endosomal-dependent mitophagy during sepsis-induced acute lung injury. Int J Surg. 2024 Mar 4. doi: 10.1097/JS9.0000000000001215. Epub ahead of print. PMID: 38445453. 2. Fan H, Yang HC, You L, Wang YY, He WJ, Hao CM. The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int. 2013 Mar;83(3):404-13. doi: 10.1038/ki.2012.394. Epub 2013 Jan 9. PMID: 23302720.

1: Valero T. Mitochondrial biogenesis: pharmacological approaches. Curr Pharm Des. 2014;20(35):5507-9. doi: 10.2174/138161282035140911142118. PMID: 24606795. 2: Duan JL, Ruan B, Song P, Fang ZQ, Yue ZS, Liu JJ, Dou GR, Han H, Wang L. Shear stress-induced cellular senescence blunts liver regeneration through Notch-sirtuin 1-P21/P16 axis. Hepatology. 2022 Mar;75(3):584-599. doi: 10.1002/hep.32209. Epub 2021 Dec 7. PMID: 34687050. 3: Zhang Y, Li T, Pan M, Wang W, Huang W, Yuan Y, Xie Z, Chen Y, Peng J, Li X, Meng Y. SIRT1 prevents cigarette smoking-induced lung fibroblasts activation by regulating mitochondrial oxidative stress and lipid metabolism. J Transl Med. 2022 May 14;20(1):222. doi: 10.1186/s12967-022-03408-5. PMID: 35568871; PMCID: PMC9107262. 4: Lian L, Le Z, Wang Z, Chen YA, Jiao X, Qi H, Hejtmancik JF, Ma X, Zheng Q, Ren Y. SIRT1 Inhibits High Glucose-Induced TXNIP/NLRP3 Inflammasome Activation and Cataract Formation. Invest Ophthalmol Vis Sci. 2023 Mar 1;64(3):16. doi: 10.1167/iovs.64.3.16. PMID: 36881408; PMCID: PMC10007902. 5: Wen Q, Wang Y, Pan Q, Tian R, Zhang D, Qin G, Zhou J, Chen L. MicroRNA-155-5p promotes neuroinflammation and central sensitization via inhibiting SIRT1 in a nitroglycerin-induced chronic migraine mouse model. J Neuroinflammation. 2021 Dec 10;18(1):287. doi: 10.1186/s12974-021-02342-5. PMID: 34893074; PMCID: PMC8665643. 6: Hammer SS, Vieira CP, McFarland D, Sandler M, Levitsky Y, Dorweiler TF, Lydic TA, Asare-Bediako B, Adu-Agyeiwaah Y, Sielski MS, Dupont M, Longhini AL, Li Calzi S, Chakraborty D, Seigel GM, Proshlyakov DA, Grant MB, Busik JV. Fasting and fasting-mimicking treatment activate SIRT1/LXRα and alleviate diabetes- induced systemic and microvascular dysfunction. Diabetologia. 2021 Jul;64(7):1674-1689. doi: 10.1007/s00125-021-05431-5. Epub 2021 Mar 26. PMID: 33770194; PMCID: PMC8236268. 7: Lee J, You JH, Kim MS, Roh JL. Epigenetic reprogramming of epithelial- mesenchymal transition promotes ferroptosis of head and neck cancer. Redox Biol. 2020 Oct;37:101697. doi: 10.1016/j.redox.2020.101697. Epub 2020 Aug 28. PMID: 32896720; PMCID: PMC7484553. 8: Ye Z, Xia Y, Li L, Li B, Chen L, Yu W, Ruan Y, Rao T, Zhou X, Cheng F. p53 deacetylation alleviates calcium oxalate deposition-induced renal fibrosis by inhibiting ferroptosis. Biomed Pharmacother. 2023 Aug;164:114925. doi: 10.1016/j.biopha.2023.114925. Epub 2023 May 24. PMID: 37236026.